Navigation Links
Driving Predictability in Clinical Development through Innovation, An Interactive Webinar Hosted by Xtalks
Date:6/11/2013

Toronto, Canada (PRWEB) June 11, 2013

The biopharmaceutical industry is caught between mounting pressure to reduce development costs and the need to ensure better outcomes from clinical trials.

Generics, lower approval rates, and global testing requirements have increased drug development costs. Yet, outcomes have remained uncertain in terms of both regulatory approval and market acceptance, and large payers continue to exert downward pressure on prices.

Although the stakes continue to increase, changing regulatory guidelines and advanced data collection methods are creating new opportunities to streamline and better focus the clinical trial process. This has the potential to reduce costs, improve trial predictability and accelerate the time it takes to bring a compound to market.

This webinar will explore the direction clinical research is headed and the role innovation plays in its new course. An expert panel, featuring speakers from INC Research, will share insights on how adapting the process of clinical development at strategic points and implementing new strategies can result in reduced cost and development time. Speakers will also discuss the value of optimizing protocols against development needs and the value of a holistic, end-to-end, approach to optimize trial delivery.

This webinar will present operational plans that are fit for purpose and that leverage leading technology for greater efficiency and predictability in conducting clinical research. Join us for an exciting, interactive discussion!

To learn more about the event, visit:
http://www.xtalks.com/clinical-process-innovation.ashx

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year, thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com/ContactUs.ashx

Contact:
Karen Lim 416-977-6555 ext. 227
clientservices(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/6/prweb10818133.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. GenScript Rush Gene Synthesis - Driving Molecular Biology Research Faster
2. Lupus Research Institute Awards $3.6 Million for Novel Studies Driving Wide-Ranging New Science in Lupus
3. Andain Inc. Announces 2,000 Units Initial Production of the Breakthrough Miniature Disposable Insulin Pump for Use in Clinical Trials for Type-I and Type-II Diabetes
4. Clinical Development, Contracts and Outsourcing in MENA & APAC, New Webinar Hosted by Xtalks
5. Clinovo Sponsors the First Outsourcing in Clinical Trials: Medical Devices & Diagnostics Conference, June 12-13, 2013 in Saint Paul, Minnesota
6. SentoClone International AB Significantly Strengthens its Global Patent Portfolio Covering its Clinical Stage Sentinel Node-derived CD4 T-cell Cancer Therapy
7. Actinium Pharmaceuticals Acute Myeloid Leukemia Clinical Data to be Presented Today at 8th International Symposium on Targeted Alpha Therapy Conference
8. Patheon to Host Complimentary Seminar on “Formulation, Funding and First-in-Man: A Stepwise Guide to Clinical Success”
9. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
10. National Brain Tumor Society Responds to Results of Avastin Clinical Trials
11. AbbVie Presents Results from Phase I Study of Investigational Oncology Compound ABT-199 at American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... LAKE, N.J. , Dec. 5, 2016 /PRNewswire/ ... Phase 3 open-label two-year study of rufinamide, which ... the American Epilepsy Society (AES) held from December ... Analysis of final two-year safety, tolerability and cognitive ... with rufinamide experienced similar safety and tolerability profiles, ...
(Date:12/4/2016)...  In five studies being presented today during the ... Exposition in San Diego , researchers ... delivery of life-saving treatments to patients with a variety ... carry therapies directly to the sites in the body ... substantial advantage over traditional, systemic methods. The studies highlight ...
(Date:12/2/2016)... OAKS, Calif. , Dec. 2, 2016 Amgen ... AGN ) today announced the submission of a Marketing ... ABP 215, a biosimilar candidate to Avastin ® (bevacizumab). ... application submitted to the EMA. "The submission ... as Amgen seeks to expand our oncology portfolio," said ...
(Date:12/2/2016)... ... December 01, 2016 , ... Aerocom Healthcare ( ... hospitals, will present its chain-of-custody solution for tracking and securing medications at booth ... Dec. 4-8, 2016. , Aerocom has a proven solution for tracking medications via ...
Breaking Biology Technology:
(Date:6/20/2016)... DALLAS , June 20, 2016 ... criminal justice technology solutions for public safety, investigation, ... by the prisons involved, it has secured the ... Corrections (DOC) facilities for Managed Access Systems (MAS) ... (4) additional facilities to be installed by October, ...
(Date:6/9/2016)... 2016 Paris Police Prefecture ... security solution to ensure the safety of people and operations ... the major tournament Teleste, an international technology group ... announced today that its video security solution will be utilised ... up public safety across the country. The system roll-out is ...
(Date:6/2/2016)... YORK , June 2, 2016   The Weather ... is announcing Watson Ads, an industry-first capability in which consumers ... by being able to ask questions via voice or text ... Marketers have long sought ... the consumer, that can be personal, relevant and valuable; and ...
Breaking Biology News(10 mins):